Why Aren’t Cardiologists Prescribing Vitamin K2?

Scientific concepts & nature/medical phenomena presented

• Vitamin K2 and arterial calcification

  • The artery wall protein matrix GLA protein (MGP) helps prevent calcium deposition in arterial walls.
  • Vitamin K2 “activates” MGP (described as the “switch”); without sufficient K2, MGP remains inactive, allowing calcium to deposit.

• Dietary vitamin K2 and coronary heart disease (observational evidence)

  • A study based on dietary recall in suburbs of Rotterdam (nearly 5,000 people aged >55) tracked deaths over ~7 years.
  • Individuals in the highest vs. lowest intake groups showed lower coronary heart disease mortality (e.g., ~57% lower for the highest third; ~27% lower for the middle third).
  • Vitamin K2 sources mentioned: cheese and egg yolks (at the time, “unknown” to many people).

• Calcium as a progression marker vs. plaques as the cause

  • The transcript distinguishes:
    • Plaque initiation: cholesterol enters the artery wall and becomes trapped.
    • Young/vulnerable plaque: relatively soft, “alive,” can rupture → heart attack.
    • Calcified plaque: older/hardened; less likely to rupture, but reflects chronic progression.
  • Calcium scans measure the later/final stage (calcification), which may correlate with risk but doesn’t necessarily prove reducing calcification reduces events.

• Mechanistic/biomarker rationale

  • Higher arterial calcification is associated with more events (example given: ~7,000-person scan study where faster calcium rise correlated with more heart attacks).

Randomized controlled trials (RCTs) testing vitamin K2 to slow calcification

Denmark trial (aortic valve calcification; published 2022)

• Participants: 365 men, ages 65–74
• Intervention: 720 µg vitamin K2/day + vitamin D for 2 years
• Comparator: placebo
• Rationale for adding vitamin D: vitamin D is said to increase MGP quantity, while K2 activates MGP.
• Outcome: described as unsuccessful for the primary question, but with a subgroup finding:
  • For participants with coronary calcium >400, vitamin K2 appeared to slow further buildup.
• Serious events: 3 with vitamin K2 vs 10 with placebo (reported as statistically significant in the transcript).

VitaK CAC study (Netherlands; published June 10, 2026)

• Participants: 180 adults with coronary calcium scores 50–400 (moderate disease)
• Intervention: 360 µg vitamin K2 (MK-7)/day
• Comparator: placebo
• After 2 years: calcium increased ~22 units less with vitamin K2 (statistically significant).

DanCode trial (Denmark; published Aug 28, 2026)

• Participants: 398 people with severe coronary heart disease, calcium around ~400
• Intervention: 720 µg vitamin K2 (MK-7)/day + vitamin D (1,000 IU)
• Comparator: placebo
• After 2 years: calcium increased ~52 units less with vitamin K2.

Soft (vulnerable) vs. calcified plaques—key uncertainty

• The transcript claims:
  • VitaK CAC found no significant difference in the number of soft plaques between vitamin K2 and placebo.
  • DanCode similarly reported no significant difference in total plaque volume / non-calcified plaques.
• Suggested implication in the transcript:
  • If calcification slows while soft plaque counts stay the same, the soft-to-calcified ratio might worsen—raising uncertainty about whether heart attack risk truly decreases.

Evidence gap: lowering coronary calcium vs. proving fewer cardiovascular events

• A large Danish effort (described as testing early detection/treatment of calcification; 31,000 men, ~7 years) reportedly could not prove mortality reduction.
• An editorial in Circulation is cited as concluding there is no direct prospectively validated evidence that reducing coronary artery calcification reduces cardiovascular events.

Dose comparison and “megadose” framing

• Trial doses: 360–720 µg/day
• Adequate intake mentioned: 90–120 µg/day
• Dietary intake vs trial doses: the transcript claims trials used roughly 10–20× more than diet alone.
• Rotterdam data: lowest-risk group consumed about ~33 µg/day; the transcript contrasts this with 720 µg (~20× higher), arguing K2 at these levels should be treated like a medicine requiring proven safety and event reduction.

Safety considerations with anticoagulants

• Warfarin: warned to be “extremely careful” with vitamin K due to interaction.
• Newer anticoagulants (examples named): apixaban, rivaroxaban, dabigatran generally not subject to the same concern (as described in the transcript), and thus were often allowed in studies.

Broader analogy: HDL-raising failures

• The transcript compares to drugs that raise HDL (“good cholesterol”) but worsened outcomes—used to argue that promising surrogate markers/biomarkers can fail in clinical outcomes.

Bone health claims for vitamin K

• European Food Safety Authority (EFSA): allowed causal claims for dietary vitamin K intake and maintenance of bone health (as framed in the transcript).
• A bone-related study is mentioned:
  • 180 µg/day vitamin K for 3 years
  • Reported: slowed bone density loss in spine and hip in postmenopausal women
  • Limitation stated: density measured; fracture risk reduction not proven.

---

Methodology / study designs outlined (bullet list)

• Rotterdam observational cohort (diet recall → mortality)

  • Recruit ~5,000 adults >55
  • Collect dietary intake (door-to-door question: “What do you eat?”)
  • Follow deaths over ~7 years
  • Compare coronary heart disease mortality across intake tertiles of vitamin K2

• Randomized controlled trial framework (calcification endpoints)

  • Denmark (2022): vitamin K2 + vitamin D vs placebo; primary focus on aortic valve calcification; analyze subgroups by baseline coronary calcium
  • VitaK CAC (Netherlands, 2026): moderate coronary calcium (50–400); K2 (MK-7) vs placebo; 2-year follow-up; compare change in calcium
  • DanCode (Denmark, 2026): severe coronary calcium (~400); K2 (MK-7) + vitamin D vs placebo; 2-year follow-up; compare change in calcium

• Plaque-type assessment approach (soft vs calcified plaques)

  • Evaluate whether vitamin K2 changes:
    • number of soft (non-calcified) plaques
    • total plaque volume and non-calcified plaques
  • Compare these between vitamin K2 and placebo groups

---

Researchers / sources mentioned (as named in the transcript)

• Dr. DiNicolantonio (spelled as “DiNicolatonio” in the transcript)
• Danish Heart Foundation
• Non-profit sponsors (unnamed)
• Circulation (journal) — editorial mentioned (author/editor not specified)
• European Food Safety Authority (EFSA)
• Dr. Stanfield (author/host credited via “drstanfield.com”; no individual research author named beyond this)
• VitaK CAC study team (unnamed researchers; described as Netherlands study)

(No individual principal investigator names for Rotterdam, VitaK CAC, DanCode, or the Denmark calcification detection trial are provided in the subtitles.)